Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali M Harandi

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|April 3, 2003
Recent developments in mucosal immunomodulatory adjuvantsAli M Harandi, Joaquin Sanchez, Kristina Eriksson, et al.
Vaccine|June 12, 2012
Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpesBenjamin Wizel, Josefine Persson, Karolina Thörn, et al.
Journal of Virology|May 4, 2012
Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological diseaseStaffan Görander, Ali M Harandi, Madelene Lindqvist, et al.
Science Translational Medicine|December 15, 2015
Ebola vaccine R&D: Filling the knowledge gapsDonata Medaglini, Ali M Harandi, Tom H M Ottenhoff, et al.
Journal of Virology|May 16, 2006
Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpesSara Tengvall, Annika Lundqvist, Roselyn J Eisenberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2006
Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxinJenni Adamsson, Marianne Lindblad, Annika Lundqvist, et al.
Microbial Pathogenesis|January 23, 2026
Exploring miRNAs in Leishmania infection: from immune modulation to theranostic potentialHamzeh Sarvnaz, Shima Hadifar, Taha Masoudsinaki, et al.
NPJ Vaccines|December 22, 2017
Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infectionEmilie Bardel, Remi Doucet-Ladeveze, Cyrille Mathieu, et al.
Vaccine|October 6, 2009
Local cytokine and inflammatory responses to candidate vaginal adjuvants in miceMadelene Lindqvist, Nazanin Navabi, Marianne Jansson, et al.
Plos One|June 14, 2011
Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biologyMadelene Lindqvist, Intawat Nookaew, Ingrid Brinkenberg, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Current Opinion in Investigational Drugs (London, England : 2000)|April 3, 2003
Recent developments in mucosal immunomodulatory adjuvantsAli M Harandi, Joaquin Sanchez, Kristina Eriksson, et al.
Vaccine|June 12, 2012
Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpesBenjamin Wizel, Josefine Persson, Karolina Thörn, et al.
Journal of Virology|May 4, 2012
Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological diseaseStaffan Görander, Ali M Harandi, Madelene Lindqvist, et al.
Science Translational Medicine|December 15, 2015
Ebola vaccine R&D: Filling the knowledge gapsDonata Medaglini, Ali M Harandi, Tom H M Ottenhoff, et al.
Journal of Virology|May 16, 2006
Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpesSara Tengvall, Annika Lundqvist, Roselyn J Eisenberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2006
Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxinJenni Adamsson, Marianne Lindblad, Annika Lundqvist, et al.
Microbial Pathogenesis|January 23, 2026
Exploring miRNAs in Leishmania infection: from immune modulation to theranostic potentialHamzeh Sarvnaz, Shima Hadifar, Taha Masoudsinaki, et al.
NPJ Vaccines|December 22, 2017
Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infectionEmilie Bardel, Remi Doucet-Ladeveze, Cyrille Mathieu, et al.
Vaccine|October 6, 2009
Local cytokine and inflammatory responses to candidate vaginal adjuvants in miceMadelene Lindqvist, Nazanin Navabi, Marianne Jansson, et al.
Plos One|June 14, 2011
Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biologyMadelene Lindqvist, Intawat Nookaew, Ingrid Brinkenberg, et al.
Pageof 8